Cargando…

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users

Detalles Bibliográficos
Autores principales:	Tossonian, HK, Raffa, JD, Alenezi, O, Anderson, K, Jassemi, S, Wight, K, DeVlaming, S, Conway, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113038/ http://dx.doi.org/10.1186/1758-2652-13-S4-P36

Ejemplares similares

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
por: Tossonian, Harout K, et al.
Publicado: (2007)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
por: Cassetti, I, et al.
Publicado: (2010)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
por: Bukkems, Vera E., et al.
Publicado: (2021)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
por: Hall, Nolwenn, et al.
Publicado: (2022)

Efficacy and safety of once daily dosing of colistin to critically ill patients
por: Skiada, A, et al.
Publicado: (2010)

Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy?
por: Vasudevan, Janani, et al.
Publicado: (2012)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Neurodegeneration in the HAART era
por: Brew, Bruce J
Publicado: (2010)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
por: Grant, A, et al.
Publicado: (2010)

HIV/HAART and the brain — what's going on?
por: Portegies, P
Publicado: (2010)

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
por: Ashby, J, et al.
Publicado: (2010)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

High level of adherence to HAART among refugees and internally displaced persons on HAART in western equatorial region of Southern Sudan
por: Salami, O, et al.
Publicado: (2010)

Tolerability of antiretroviral therapy (HAART) in elderly age
por: Celesia, B M
Publicado: (2010)

Metropolitan Social Environments and Pre-HAART/HAART Era Changes in Mortality Rates (per 10,000 Adult Residents) among Injection Drug Users Living with AIDS
por: Friedman, Samuel R., et al.
Publicado: (2013)

Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
por: Onigbogi, MO, et al.
Publicado: (2010)

ONCE DAILY LITHIUM IN THE PROPHYLAXIS OF MOOD DISORDERS
por: Mohan, Rajesh, et al.
Publicado: (1996)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia
por: Garrido, C, et al.
Publicado: (2010)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

The prognosis of patients with dissociated virological and immunological responses to HAART
por: Jevtovic, DJ, et al.
Publicado: (2010)

Blindingly obvious (once revealed): a novel approach to blinding medicinal products for injection
por: Sanders, Julia, et al.
Publicado: (2015)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
por: Sension, M, et al.
Publicado: (2010)

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
por: Qaqish, R, et al.
Publicado: (2010)

Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
por: Doroana, M, et al.
Publicado: (2010)

HIV-1 infection in dendritic cells in HAART suppressed patients
por: Maldonado, lrvin M, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_sbrrr8jfj6k3efgko8vkm2dcb5